Novo Nordisk A/S (NVO) 12-Month Stock Forecast & Price Target Cone
Novo Nordisk A/S (NVO) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Drag to Test Your NVO Position Size: $10,000
Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)
Street Historical Accuracy: 64/100| Wall Street Firm | Stance | 12M Target | 1Y Accuracy | Track Grade |
|---|---|---|---|---|
| Morgan StanleyInstitutional Equity Desk | HOLD | $42 | 74% | A |
| Goldman SachsSector Coverage Lead | BUY | $63 | 69% | B |
| JP MorganUS Large-Cap Research | HOLD | $36 | 58% | C |
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live NVO Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
NVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NVO today. View full Setup Ledger →
NVO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhat is NVO's 12-month stock price target?
Novo Nordisk A/S (NVO) carries a 12-month consensus base price target of $40.55 (+3.6% from $39.14), with a bull-case target of $67.37 and a bear-case floor of $31.63.
Is NVO stock a Buy, Hold, or Sell right now?
Roarable's 5-Pillar RQD Quant Engine rates NVO C+ (Hold — HOLD) with an RQD Confidence score of 66/100.